Analystreport

BioScrip Inc (NASDAQ: BIOS) had its price target lowered by analysts at Canaccord Genuity from $5.00 to $3.50. They now have a "buy" rating on the stock.

BioPlus Acquisition Corp.  (BIOS) 
Last bioplus acquisition corp. earnings: 11/6 06:00 am Check Earnings Report
US:NASDAQ Investor Relations: bioscrip.com/investors